Medunik USA announced the FDA approval of Pheburane (sodium phenylbutyrate) for the off-label treatment of urea cycle disorders, aiming to expand a limited treatment landscape that currently faces significant regulatory barriers and market access challenges. Pheburane offers potential competitive advantages over existing therapies by utilizing a nonpeptide mechanism to support nitrogen scavenging without the injection requirements of peptide-based competitors.